RU2003113328A - Профилактическое и терапевтическое средство для лечения осложнений, связанных с диабетом - Google Patents

Профилактическое и терапевтическое средство для лечения осложнений, связанных с диабетом Download PDF

Info

Publication number
RU2003113328A
RU2003113328A RU2003113328/15A RU2003113328A RU2003113328A RU 2003113328 A RU2003113328 A RU 2003113328A RU 2003113328/15 A RU2003113328/15 A RU 2003113328/15A RU 2003113328 A RU2003113328 A RU 2003113328A RU 2003113328 A RU2003113328 A RU 2003113328A
Authority
RU
Russia
Prior art keywords
treatment
diabetes
prevention
diabetic
formula
Prior art date
Application number
RU2003113328/15A
Other languages
English (en)
Inventor
Масаки КИТАХАРА (JP)
Масаки КИТАХАРА
Ясуси САИТО (JP)
Ясуси САИТО
Сейдзиро МОРИ (JP)
Сейдзиро МОРИ
Минору ТАКЕМОТО (JP)
Минору ТАКЕМОТО
Таро ТАМАКИ (JP)
Таро ТАМАКИ
Original Assignee
Ниссан Кемикал Индастриз, Лтд (Jp)
Ниссан Кемикал Индастриз, ЛТД
Кова Компани, Лтд. (Jp)
Кова Компани, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ниссан Кемикал Индастриз, Лтд (Jp), Ниссан Кемикал Индастриз, ЛТД, Кова Компани, Лтд. (Jp), Кова Компани, Лтд. filed Critical Ниссан Кемикал Индастриз, Лтд (Jp)
Publication of RU2003113328A publication Critical patent/RU2003113328A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)

Claims (4)

1. Лекарственное средство для профилактики и/или лечения осложнений, связанных с диабетом, включающий соединение, представленное формулой (1)
Figure 00000001
где R представляет органическую группу;
Х является -CH2СН2- или -СН=СН-;
М представляет атом водорода, C1-10 алкильную группу или физиологически приемлемую катионную группу,
или его лактонизированная форма, в качестве активного ингредиента.
2. Лекарственное средство для профилактики и/или лечения осложнений, связанных с диабетом по п.1, где R является группой с циклической структурой, выбранной из индолильной, инденильной, пиридильной, пирролопиридильной, пиразолопиридильной, тиенопиридильной, пиримидинильной, пиразолильной, пирролильной, имидазолильной, индолизинильной, хинолильной, нафтильной, гексагидронафтильной, циклогексильной, фенилсилилфенильной, фенилтиенильной и фенилфурильной группы.
3. Лекарственное средство для профилактики и/или лечения осложнений, связанных с диабетом по п.2, где соединение, представленное формулой (1), является ловастатином, правастатином, симвастатином, флуваситатином, серивастатином, аторвастатином, росувастатином или кальциевой солью (+)-бис{(3R,5S,6Е)-7-[2-циклопропил-4-(4-фторфенил)-3-хинолил]-3,5-дигидрокси-6-гептеновой кислоты}.
4. Лекарственное средство для профилактики и/или лечения осложнений, связанных с диабетом по п.3, где соединение, представленное формулой (1), является кальциевой солью (+)-бис{(3R, 5S,6Е)-7-[2-циклопропил-4-(4-фторфенил)-3-хинолил]-3,5-дигидрокси-6-гептеновой кислоты}.
RU2003113328/15A 2000-10-12 2001-10-11 Профилактическое и терапевтическое средство для лечения осложнений, связанных с диабетом RU2003113328A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000311960 2000-10-12
JP2000-311960 2000-10-12

Publications (1)

Publication Number Publication Date
RU2003113328A true RU2003113328A (ru) 2004-09-10

Family

ID=18791637

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003113328/15A RU2003113328A (ru) 2000-10-12 2001-10-11 Профилактическое и терапевтическое средство для лечения осложнений, связанных с диабетом

Country Status (21)

Country Link
US (1) US20040087597A1 (ru)
EP (1) EP1325745B1 (ru)
JP (1) JPWO2002030425A1 (ru)
KR (1) KR100830018B1 (ru)
CN (1) CN1230173C (ru)
AT (1) ATE401886T1 (ru)
AU (2) AU2001294221B2 (ru)
CA (1) CA2424060A1 (ru)
CZ (1) CZ2003934A3 (ru)
DE (1) DE60135000D1 (ru)
HK (1) HK1060311A1 (ru)
HU (1) HUP0303353A3 (ru)
IL (1) IL155173A0 (ru)
MX (1) MXPA03003204A (ru)
NO (1) NO20031678L (ru)
NZ (1) NZ525150A (ru)
PL (1) PL361097A1 (ru)
RU (1) RU2003113328A (ru)
SK (1) SK4112003A3 (ru)
WO (1) WO2002030425A1 (ru)
ZA (1) ZA200302507B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4235000B2 (ja) * 2001-04-19 2009-03-04 興和株式会社 糸球体疾患治療剤
EP1614429A4 (en) * 2003-04-17 2007-05-02 Kowa Co LKLF / KLF2 GEN-EXPRESSIONSPROMOTER
JP2005232151A (ja) * 2003-04-28 2005-09-02 Iichiro Shimomura 糖取り込み能増強剤
EP1621210B1 (en) * 2003-04-28 2013-06-19 Daiichi Sankyo Company, Limited Adiponectin production enhancer
US7772272B2 (en) 2003-04-28 2010-08-10 Daiichi Sankyo Company, Limited Method for enhancing glucose uptake into warm-blooded animal adipocytes
CN100368374C (zh) * 2003-05-23 2008-02-13 兴和株式会社 羧酸化合物及含有该化合物的医药
WO2006064825A1 (ja) * 2004-12-14 2006-06-22 Santen Pharmaceutical Co., Ltd. ドライアイ治療剤
EP1785133A1 (en) * 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy
EP2626069A4 (en) * 2010-10-06 2014-03-19 Univ Tokyo A MEDICINAL PRODUCT FOR THE PREVENTION AND TREATMENT OF A DERY LYMPH

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (ru) * 1974-06-07 1981-03-18
US4346772A (en) * 1978-01-03 1982-08-31 Clifft Dale L Power assisting device for a manually operating vehicle
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4588715A (en) * 1984-06-04 1986-05-13 Sandoz, Inc. Heptenoic acid derivatives
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4804679A (en) * 1984-07-24 1989-02-14 Sandoz Pharm. Corp. Erythro-(E)-7-(3'-C1-3alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl)-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US5001255A (en) * 1984-12-04 1991-03-19 Sandoz Pharm. Corp. Idene analogs of mevalonolactone and derivatives thereof
US4851427A (en) * 1985-10-25 1989-07-25 Sandoz Pharm. Corp. Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use
US4829081A (en) * 1986-01-07 1989-05-09 Sandoz Pharm. Corp. Analogs of mevalonolactone and derivatives thereof
US4927851A (en) * 1986-01-07 1990-05-22 Sandoz Pharm. Corp. Analogs of mevalonolactone and derivatives thereof
US4939159A (en) * 1986-09-10 1990-07-03 Sandoz Pharm. Corp. Azaindole derivatives useful as cholesterol biosynthesis inhibitors
US4751235A (en) * 1986-12-23 1988-06-14 Sandoz Pharm. Corp. Anti-atherosclerotic indolizine derivatives
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
EP0308736A3 (en) * 1987-09-12 1990-02-14 Nissan Chemical Industries Ltd. Pyrimidine type mevalonolactones
US4868185A (en) * 1987-12-10 1989-09-19 Warner-Lambert Company 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4822799A (en) * 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
FI894648A (fi) * 1988-10-03 1990-04-04 Glaxo Group Ltd Kemiska foereningar.
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
DK1099694T3 (da) * 1998-07-23 2005-09-19 Nissan Chemical Ind Ltd Fremgangsmåde til fremstilling af quinolinderivat og mellemprodukt derfor
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
EP1161236A1 (en) * 1999-03-08 2001-12-12 Merck & Co., Inc. Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
EP1253925A1 (en) * 2000-01-28 2002-11-06 Bristol-Myers Squibb Company Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
US8186012B2 (en) * 2004-06-03 2012-05-29 The Wooster Brush Company Pole grip with storage compartment

Also Published As

Publication number Publication date
AU2001294221B2 (en) 2005-09-29
SK4112003A3 (en) 2004-01-08
DE60135000D1 (de) 2008-09-04
HUP0303353A3 (en) 2004-10-28
WO2002030425A1 (fr) 2002-04-18
CA2424060A1 (en) 2003-03-31
AU9422101A (en) 2002-04-22
IL155173A0 (en) 2003-10-31
CN1469745A (zh) 2004-01-21
HUP0303353A2 (hu) 2004-01-28
NO20031678D0 (no) 2003-04-11
HK1060311A1 (en) 2004-08-06
NZ525150A (en) 2004-10-29
PL361097A1 (en) 2004-09-20
ATE401886T1 (de) 2008-08-15
ZA200302507B (en) 2004-03-31
EP1325745A4 (en) 2005-07-13
EP1325745A1 (en) 2003-07-09
JPWO2002030425A1 (ja) 2004-02-19
MXPA03003204A (es) 2004-12-03
NO20031678L (no) 2003-04-11
US20040087597A1 (en) 2004-05-06
CN1230173C (zh) 2005-12-07
KR100830018B1 (ko) 2008-05-15
CZ2003934A3 (cs) 2003-11-12
KR20030060905A (ko) 2003-07-16
EP1325745B1 (en) 2008-07-23

Similar Documents

Publication Publication Date Title
CA2536187C (en) Pharmaceutical composition comprising a combination of metformin and a statin
KR101071192B1 (ko) 고안압증과 녹내장의 치료용 스타틴
RU2012116079A (ru) Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения
KR20060135826A (ko) 외용제
RU2003113328A (ru) Профилактическое и терапевтическое средство для лечения осложнений, связанных с диабетом
US20150272944A1 (en) Novel triglyceride reducing agent
KR20090127904A (ko) 스타틴과 항비만제의 복합물
JP2012520279A (ja) ロスバスタチンおよびアトルバスタチン誘導体
JP2002536405A (ja) ウイルス感染症の治療方法
ATE101138T1 (de) Parabansaeure-derivate und pharmazeutische zusammensetzungen damit.
DK0911026T3 (da) Creatinderivater for astma
JP2005522490A5 (ru)
JP4630065B2 (ja) 外用剤
JPWO2006011495A1 (ja) 高コレステロール血症及び／又は高トリグリセリド血症治療剤
US20130210860A1 (en) Prophylactic and/or therapeutic agent against lymphedema
FI964303A0 (fi) Keuhkosydänvian hoitamiseen tarkoitettu aine
JP5308788B2 (ja) 貼付剤
JP4719572B2 (ja) Ｌｋｌｆ／ｋｌｆ２遺伝子発現促進剤
RU2002133205A (ru) Новый препарат
US20040048805A1 (en) Antilipemic agents
TH52206A (th) สารที่รวมเข้าด้วยกันของ สแททิน-คาร์บอกซิแอลคิลอีเธอร์
JPWO2005117853A1 (ja) 高脂血症治療剤及び糖尿病治療剤

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20060405